Author:
Ivanov B. M.,Antipova O. M.,Sliman Ya. A.,Samoylenkova N. S.,Pronin I. N.,Pavlova G. V.,Kopylov A. M.
Publisher
Springer Science and Business Media LLC
Reference12 articles.
1. Ai, S., Duan, J., Liu, X., et al., “Biological evaluation of a novel doxorubicin−peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells,” Mol. Pharm., 8, No. 2, 375–386 (2011).
2. Akhtar, N., Mohammed, H. A., Yusuf, M., et al., “SPIONs conjugate supported anticancer drug doxorubicin’s delivery: current status, challenges, and prospects,” Nanomaterials, 12, No. 20, 3686 (2022).
3. Alieva, R. R., Zavyalova, E. G., Tashlitsky, V. N., and Kopylov, A. M., “Quantitative characterization of oligomeric state of G-quadruplex antithrombin aptamers by size exclusion HPLC,” Mendeleev Comm., 29, No. 4, 424–425 (2019).
4. Horbinski, C., Berger, T., Packer, R. J., and Wen, P. Y., “Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours,” Nat. Rev. Neurol., 18, No. 9, 515–529 (2022).
5. Kopylov, A. M., Fab, L. V., Antipova, O., et al., “RNA aptamers for theranostics of glioblastoma of human brain,” Biochemistry (Mosc.), 86, 1012–1024 (2021).